Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The financial information indicates a generally positive trend in free cash flow to the firm (FCFF) between 2021 and 2024, followed by a slight decrease in the most recent year presented. Net cash provided by operating activities exhibits more volatility, though remains substantial throughout the period.
- Free Cash Flow to the Firm (FCFF)
- FCFF increased from US$7,294 million in 2021 to US$8,747 million in 2024, representing a cumulative growth of approximately 20.1%. This suggests improving cash generation capabilities over this timeframe. However, FCFF experienced a modest decline to US$7,828 million in 2025, a decrease of approximately 10.4% from the 2024 peak. This recent decrease warrants further investigation to determine its underlying causes.
- Net Cash from Operating Activities
- Net cash provided by operating activities began at US$9,312 million in 2021, decreased to US$9,154 million in 2022, then declined further to US$8,406 million in 2023. A recovery was observed in 2024, with operating cash flow rising to US$8,667 million. The final year, 2025, saw a further decrease to US$7,818 million. While remaining consistently positive, the fluctuations in operating cash flow suggest potential variability in the company’s core business activities or working capital management.
The relationship between FCFF and net cash from operating activities suggests that factors beyond core operations, such as capital expenditures or changes in working capital, significantly influence FCFF. The divergence between the two metrics, particularly in 2023 and 2025, indicates that these non-operating factors are playing an increasingly important role in the company’s overall cash flow profile.
Overall, the trend in FCFF demonstrates a period of growth followed by a recent contraction. Continued monitoring of both FCFF and net cash from operating activities is recommended to understand the sustainability of cash generation and the drivers behind the observed fluctuations.
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2 2025 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =
A significant increase in cash paid for interest, net of tax, is observed over the five-year period. Simultaneously, the effective income tax rate demonstrates considerable fluctuation. These trends are examined in further detail below.
- Cash Paid for Interest, Net of Tax
- Cash paid for interest, net of tax, increased substantially from US$485 million in 2021 to US$607 million in 2022, representing a 25.15% increase. This upward trend continued with a more pronounced rise to US$1,323 million in 2023, a 117.93% increase from the prior year. The rate of increase moderated in subsequent years, with increases of 7.56% to US$1,423 million in 2024 and 3.38% to US$1,491 million in 2025. The consistent growth suggests increasing debt levels or rising interest rates, or a combination of both, impacting the company’s financing costs.
- Effective Income Tax Rate
- The effective income tax rate exhibited volatility throughout the period. It decreased from 12.54% in 2021 to 8.97% in 2022, a decline of 28.76%. A more substantial decrease followed in 2023, falling to 4.51%, representing a 49.78% reduction from 2022. The rate increased to 9.34% in 2024, before decreasing again to 7.50% in 2025. These fluctuations could be attributed to changes in tax legislation, geographic earnings mix, or the realization of tax benefits or liabilities.
- Relationship between Interest Paid and Effective Income Tax Rate
- The substantial increase in interest paid, net of tax, occurred alongside a significant decrease in the effective income tax rate in 2023. While not necessarily causally linked, this combination could indicate strategic tax planning related to debt financing. The subsequent increase in the effective income tax rate in 2024 did not significantly curtail the growth in net interest paid, suggesting that the underlying drivers of interest expense remained strong. The slight decrease in the effective income tax rate in 2025, coupled with continued growth in net interest paid, reinforces this observation.
Further investigation into the company’s debt structure, interest rate exposure, and tax strategies would be necessary to fully understand the observed trends.
Enterprise Value to FCFF Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | |
| Free cash flow to the firm (FCFF) | |
| Valuation Ratio | |
| EV/FCFF | |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| AbbVie Inc. | |
| Amgen Inc. | |
| Bristol-Myers Squibb Co. | |
| Danaher Corp. | |
| Eli Lilly & Co. | |
| Gilead Sciences Inc. | |
| Johnson & Johnson | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| Vertex Pharmaceuticals Inc. | |
| EV/FCFF, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | |
| EV/FCFF, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2025-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | ||||||
| Free cash flow to the firm (FCFF)2 | ||||||
| Valuation Ratio | ||||||
| EV/FCFF3 | ||||||
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| EV/FCFF, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| EV/FCFF, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio demonstrates a generally decreasing trend over the observed five-year period. While fluctuations exist, the ratio suggests a relative improvement in the company’s ability to generate free cash flow relative to its enterprise value.
- Enterprise Value (EV)
- Enterprise Value experienced a slight decrease from US$241,765 million in 2021 to US$238,371 million in 2022. It then saw a modest increase to US$240,548 million in 2023 before declining to US$228,574 million in 2024 and further to US$222,504 million in 2025. This indicates a general downward trajectory in enterprise value over the period.
- Free Cash Flow to the Firm (FCFF)
- Free Cash Flow to the Firm exhibited an increasing trend from US$7,294 million in 2021 to US$7,542 million in 2022 and continued to rise to US$8,337 million in 2023 and US$8,747 million in 2024. A slight decrease was observed in 2025, with FCFF reported at US$7,828 million. Overall, FCFF demonstrates positive growth, although with a minor contraction in the most recent year.
- EV/FCFF Ratio
- The EV/FCFF ratio decreased from 33.14 in 2021 to 31.61 in 2022, continuing downward to 28.85 in 2023 and 26.13 in 2024. The ratio experienced a slight increase in 2025, reaching 28.42. This pattern suggests that the company’s enterprise value is becoming less reliant on each dollar of free cash flow generated, potentially indicating improved efficiency or valuation adjustments. The lowest ratio was observed in 2024, suggesting the most favorable relationship between enterprise value and free cash flow during that year.
The combined trends of decreasing Enterprise Value and increasing Free Cash Flow to the Firm contribute to the observed decline in the EV/FCFF ratio. The slight increase in the ratio in 2025 warrants further investigation to determine if it represents a temporary fluctuation or the beginning of a new trend.